The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma

Abstract Osteosarcoma is the most common primary malignant bone tumor, and its standard treatment is a combination of surgery and chemotherapy. A poor response to chemotherapy causes unfavorable oncological outcomes. We investigated the correlation between osteoclast differentiation in biopsy specim...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Y. Araki, N. Yamamoto, K. Hayashi, A. Takeuchi, S. Miwa, K. Igarashi, T. Higuchi, K. Abe, Y. Taniguchi, H. Yonezawa, S. Morinaga, Y. Asano, H. Ikeda, T. Nojima, H. Tsuchiya
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4c909ec406d4498bb3b61f523b9e0488
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4c909ec406d4498bb3b61f523b9e0488
record_format	dspace
spelling	oai:doaj.org-article:4c909ec406d4498bb3b61f523b9e04882021-12-02T13:57:05ZThe number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma10.1038/s41598-020-80504-w2045-2322https://doaj.org/article/4c909ec406d4498bb3b61f523b9e04882021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80504-whttps://doaj.org/toc/2045-2322Abstract Osteosarcoma is the most common primary malignant bone tumor, and its standard treatment is a combination of surgery and chemotherapy. A poor response to chemotherapy causes unfavorable oncological outcomes. We investigated the correlation between osteoclast differentiation in biopsy specimens and the efficacy of neoadjuvant chemotherapy in resected specimens. Forty-nine patients who underwent neoadjuvant chemotherapy and subsequent surgical treatment at our institution between 1999 and 2018 were enrolled. Using medical records, we investigated the age, sex, tumor size, location, subtype, staging, chemotherapy agents (doxorubicin, cisplatin, ifosfamide, and methotrexate), number of neoadjuvant chemotherapy courses, number of osteoclasts in biopsy specimens, and efficacy of neoadjuvant chemotherapy according to the Rosen and Huvos classification (Grade I-IV) in resected specimens. Univariate and multivariate analyses were performed to identify factors predictive of a good response in resected specimens after neoadjuvant chemotherapy. A good response (Grade III/IV) was detected in 25, while a poor response (Grade I/II) was detected in 24. According to the multivariate analysis, ≥ 46 years old (odds ratio [OR], 0.05; 95% confidence interval [CI], 0.01–0.45; p < 0.01) and ≥ 5 mature osteoclasts in a biopsy specimen (OR, 36.9; 95% CI, 6.03–225; p < 0.01) were significantly associated with the neoadjuvant chemotherapy efficacy. The accuracy for predicting a good response to chemotherapy based on ≥ 5 osteoclasts in a biopsy specimen in patients < 46 years old was 85%. The number of mature osteoclasts in biopsy specimens is a simple factor for predicting the efficacy of chemotherapy before treatment, although further studies will be required to determine the underlying mechanism.Y. ArakiN. YamamotoK. HayashiA. TakeuchiS. MiwaK. IgarashiT. HiguchiK. AbeY. TaniguchiH. YonezawaS. MorinagaY. AsanoH. IkedaT. NojimaH. TsuchiyaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Y. Araki N. Yamamoto K. Hayashi A. Takeuchi S. Miwa K. Igarashi T. Higuchi K. Abe Y. Taniguchi H. Yonezawa S. Morinaga Y. Asano H. Ikeda T. Nojima H. Tsuchiya The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
description	Abstract Osteosarcoma is the most common primary malignant bone tumor, and its standard treatment is a combination of surgery and chemotherapy. A poor response to chemotherapy causes unfavorable oncological outcomes. We investigated the correlation between osteoclast differentiation in biopsy specimens and the efficacy of neoadjuvant chemotherapy in resected specimens. Forty-nine patients who underwent neoadjuvant chemotherapy and subsequent surgical treatment at our institution between 1999 and 2018 were enrolled. Using medical records, we investigated the age, sex, tumor size, location, subtype, staging, chemotherapy agents (doxorubicin, cisplatin, ifosfamide, and methotrexate), number of neoadjuvant chemotherapy courses, number of osteoclasts in biopsy specimens, and efficacy of neoadjuvant chemotherapy according to the Rosen and Huvos classification (Grade I-IV) in resected specimens. Univariate and multivariate analyses were performed to identify factors predictive of a good response in resected specimens after neoadjuvant chemotherapy. A good response (Grade III/IV) was detected in 25, while a poor response (Grade I/II) was detected in 24. According to the multivariate analysis, ≥ 46 years old (odds ratio [OR], 0.05; 95% confidence interval [CI], 0.01–0.45; p < 0.01) and ≥ 5 mature osteoclasts in a biopsy specimen (OR, 36.9; 95% CI, 6.03–225; p < 0.01) were significantly associated with the neoadjuvant chemotherapy efficacy. The accuracy for predicting a good response to chemotherapy based on ≥ 5 osteoclasts in a biopsy specimen in patients < 46 years old was 85%. The number of mature osteoclasts in biopsy specimens is a simple factor for predicting the efficacy of chemotherapy before treatment, although further studies will be required to determine the underlying mechanism.
format	article
author	Y. Araki N. Yamamoto K. Hayashi A. Takeuchi S. Miwa K. Igarashi T. Higuchi K. Abe Y. Taniguchi H. Yonezawa S. Morinaga Y. Asano H. Ikeda T. Nojima H. Tsuchiya
author_facet	Y. Araki N. Yamamoto K. Hayashi A. Takeuchi S. Miwa K. Igarashi T. Higuchi K. Abe Y. Taniguchi H. Yonezawa S. Morinaga Y. Asano H. Ikeda T. Nojima H. Tsuchiya
author_sort	Y. Araki
title	The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
title_short	The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
title_full	The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
title_fullStr	The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
title_full_unstemmed	The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
title_sort	number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4c909ec406d4498bb3b61f523b9e0488
work_keys_str_mv	AT yaraki thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT nyamamoto thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT khayashi thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT atakeuchi thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT smiwa thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT kigarashi thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT thiguchi thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT kabe thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT ytaniguchi thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT hyonezawa thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT smorinaga thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT yasano thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT hikeda thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT tnojima thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT htsuchiya thenumberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT yaraki numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT nyamamoto numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT khayashi numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT atakeuchi numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT smiwa numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT kigarashi numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT thiguchi numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT kabe numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT ytaniguchi numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT hyonezawa numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT smorinaga numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT yasano numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT hikeda numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT tnojima numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma AT htsuchiya numberofosteoclastsinabiopsyspecimencanpredicttheefficacyofneoadjuvantchemotherapyforprimaryosteosarcoma
_version_	1718392319012503552

The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma

Ejemplares similares